Ljubljana 2014 Registration Programme Satellite Meetings Exhibition Hotel Information Virtual Exhibition Visa Information
Back to Freepaper Session

Superb manoeuvres in keratoconus: an almost perfect vision

Session Details

Session Title: Cornea

Session Date/Time: Sunday 16/02/2014 | 08:30-11:00

Paper Time: 10:39

Venue: Linhart Hall (Level -2)

First Author: : KhaledAbdelrahman SAUDI ARABIA

Co Author(s): :                  

Abstract Details

Purpose:

To evaluate the safety, predictability, efficacy and reliability of iris-claw intraocular lens (ARTIFLEX) & toric implantable collamer lens (TICL) as a secondary step surgical intervention in the management of moderate and advanced Keratoconus.

Setting:

Magrabi Riyadh Center, Riyadh, Saudi Arabia.

Methods:

A retrospective monitored interventional case series by single-surgeon composed of 19 eyes from 16 patients diagnosed as having either moderate or advanced Keratoconus. KP was performed on 14 eyes, CXL on 4 eyes and INTACS in one eye. Out of the 14 KP eyes, 10 did PKP, 4 did DLKP and 6 did AK after KP prior to pIOL implantation. Out of 19 eyes, 12 had TICL Implantation & 7 had Myopic Artiflex Implantation.

Results:

All the 19 eyes achieved a UCVA of 20/50 or better with mean UDVA of 20/30 + 0.131D from pre-operative mean UCVA of 20/401 + 0.544D. Mean BCVA is 20/23 + 0.118D from 20/106 + 0.605D. Post pIOL mean endothelial cell count is 2301 + 397cc2 indicating an insignificant decrease from pre pIOL mean endothelial cell count of 2314 + 397cc2.

Conclusions:

Clinical results indicate that implantation of either iris-claw intraocular lens or toric implantable collamer lens after uneventful Keratoplasty is a viable option that provides excellent refractive outcomes with insignificant endothelial cell loss. Astigmatic Keratotomy is a conventional solution in reducing the post-keratoplasty astigmatism with encouraging refractive predictability. A surgical plan involving several procedures is proven safe and effective with predictable and reliable result. FINANCIAL INTEREST: NONE